Infant Colic Treatment set for Launch in Italy

Pierre Fabre Pharma Italy has entered into an agreement to distribute Noventure’s AprotecolR a Class IIa CE marked treatment for prevention of bloating and intestinal colic in infants and young children throughout Italy. Abdominal tension and colic in this age group is thought to be caused by different factors, including leaky intestinal mucosa or the growth of gas-producing bacteria in the intestines; this treatment, available as an oily suspension for oral use, was designed to provide an effective reinforcement of the mucosal barrier and a re-balancing of the intestinal flora. Colic is a common condition worldwide with around 20% of infants younger than three-months developing the condition.

Luciano Conde, CEO of Noventure said: “Aprotecol is an innovative product that will help to improve the quality of life of young patients across Italy affected by colic and bloating as well as their parents. We firmly believe that partnering with Pierre Fabre, whose commitment to childrens’ healthcare is recognised worldwide, represents a great opportunity for Noventure to further disseminate its innovative barrier technology.”

Charles-Henri Bodin, general manger of Pierre Fabre Pharma Italy said: “Aprotecol is a great opportunity for Pierre Fabre to reinforce its position in paediatrics in Italy. Our teams are prepared and highly motivated to offer Italian paediatricians this innovative solution to treat their young patients.” The Italian company anticipates launching Aprotecol in January 2018.

Noventure’s business model is based on offering exclusive commercial rights for selected regions to its distribution partners. This treatment is being partnered by Noventure worldwide.